Document EMERGENT BIOSO LUTIONS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2

EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million

Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%

Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior year

Third Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%

Raising the Full Year 2025 Revenue and Profitability Guidance

Strong Sequential Naloxone Revenue Growth, Primarily Driven by NARCAN Nasal Spray, QoQ Through Q3 2025

GAITHERSBURG, Md., October 29, 2025-Emergent BioSolutions Inc. (NYSE EBS) today reported financial results for the third quarter ended September 30, 2025.

"Following a strong second quarter, we are proud to again beat the high end of our third quarter 2025 revenue guidance by $21 million, with continued margin expansion that gives us confidence in meeting the higher end of our adjusted EBITDA guidance for 2025," said Joe Papa, president and CEO of Emergent. "We remain confident in our products business as evidenced by the sequential growth of our naloxone franchise, where pricing has stabilized for NARCAN Nasal Spray, as well as continued demand from our international customers, who represent 34% of our medical countermeasures orders year to date. The Company has now secured eleven MCM contract modifications and product orders in 2025, highlighting the consistent global demand for medical countermeasures products, in a world where biological threats represent a growing risk. Our balance sheet is healthy, and we are judiciously deploying our capital to create shareholder value and build a long-term growth trajectory."

FINANCIAL HIGHLIGHTS (1)

Year to Date ( YTD ) 2025 vs YTD 2024

RECENT BUSINESS UPDATES

Received $29 Million in MCM product orders from international government partner

Secured $17 Million contract modification for Oral Suspension TEMBEXA (brincidofovir)

Secured $56 Million contract modification for ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live)

Secured $30 Million contract modification for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted)

Secured $52 Million contract modification award for CNJ-016 (Vaccinia Immune Globulin Intravenous, Human (VIGIV))

Updated proprietary distribution platform, NARCANDirect , to offer KLOXXADO Nasal Spray 8 mg and Convenience Kits

Recognized multiple naloxone awareness days throughout the quarter, and applauded the over-the-counter availability of naloxone in U.S. House of Representatives buildings

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

THIRD QUARTER 2025 FINANCIAL PERFORMANCE (1)

The Company uses the following categories in discussing revenues

Naloxone - comprises contributions from NARCAN Nasal Spray and KLOXXADO Nasal Spray

Anthrax MCM - comprises contributions from CYFENDUS , previously known as AV7909, BioThrax , Anthrasil and Raxibacumab

Smallpox MCM - comprises contributions from ACAM2000 , CNJ-016 (VIGIV) and TEMBEXA

Other Products - comprises contributions from BAT and RSDL (3)

All Other Revenues - comprises revenues from the Services operating segment and contracts and grants revenues

Product Sales, net (4)

For Q3 2025, revenues from Naloxone products decreased $20.4 million, or 21%, as compared with Q3 2024. The decrease was primarily driven by lower sales of OTC NARCAN and lower Canadian sales of branded NARCAN , primarily driven by an unfavorable price and volume mix, partially offset by an increase in KLOXXADO sales.

For Q3 2025, revenues from Anthrax MCM products decreased $10.0 million, or 88%, as compared with Q3 2024. The decrease primarily reflects the impact of timing of USG sales of BioThrax as well as timing of international sales of CYFENDUS in the prior year period. Anthrax vaccine product sales are primarily made under annual purchase options exercised by the U.S.

Government ( USG ). Fluctuations in revenues result from the timing of the exercise of annual purchase options, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.

For Q3 2025, revenues from Smallpox MCM products decreased $49.1 million, or 37%, as compared with Q3 2024. The decrease was primarily due to lower USG ACAM2000 and CNJ-016 (VIGIV) sales due to timing, partially offset by an increase in international CNJ-016 (VIGIV), ACAM2000 , and TEMBEXA sales. Fluctuations in revenues from Smallpox MCM result from the timing of the exercise of annual purchase options in the existing procurement contracts, the timing of USG purchases, the availability of governmental funding and Company delivery of orders that follow.

For Q3 2025, revenues from Other Product sales increased $27.4 million, or 91%, as compared with Q3 2024. The increase was primarily due to higher USG BAT sales due to timing, partially offset by a decrease in international sales orders.

For Q3 2025, revenues from Services decreased $9.7 million, or 68%, as compared with Q3 2024. The decrease was primarily attributable to the decrease in revenue from the Company's Camden facility in the current year period, which was sold to Bora Pharmaceuticals in the third quarter of 2024, partially offset by an increase in production at the Company's Winnipeg facility.

Contracts and Grants

For Q3 2025, revenues from contracts and grants decreased $0.9 million, or 9%, as compared with Q3 2024. The decrease was due to declines in overall funded R D projects, partially offset by an increase in development work in connection with EbangaTM.

Cost of Product and Services Sales, Net

For Q3 2025, cost of product and services sales, net decreased $36.7 million, or 30%, as compared with Q3 2024. The decrease was driven by decreases in cost of Services of $16.2 million, cost of MCM Product sales of $15.9 million and cost of Commercial Product sales of $4.6 million.

Research and Development Expenses

For Q3 2025, R D expenses decreased $0.3 million, or 2% as compared with Q3 2024. The decrease was primarily due to decreases in overhead and severance related costs, partially offset by an increase in unfunded R D project spend and in Ebanga related development work.

Selling, General and Administrative Expenses

For Q3 2025, SG A expenses decreased $37.7 million, or 49%, as compared with Q3 2024. The decrease was primarily due to the absence of a one-time expense of $10.0 million recognized in the prior year period and the receipt of a one-time reimbursement of $10.5 million in the current year period related to settlements of our securities and shareholder litigation matters. These non-recurring items were coupled with decreases in compensation and other employee related expenses as a result of the restructuring initiatives that began during the first quarter of 2023, and lower marketing, professional services and legal expenses.

ADDITIONAL FINANCIAL INFORMATION(1)

Capital Expenditures

For Q3 2025, capital expenditures decreased largely due to lower development activities across the Company's facilities.

REPORTABLE SEGMENT INFORMATION

The Company manages the business with a focus on three operating segments (1) a Commercial Products segment consisting of NARCAN Nasal Spray and KLOXXADO Nasal Spray, which product is currently being integrated into our distribution network, NARCANDirect (2) a MCM Products segment consisting of Anthrax - MCM, Smallpox - MCM and Other products and (3) a services segment consisting of our Bioservices offerings ("Services"). Commercial Products and MCM Products are our two reportable segments. In the first quarter of 2025, the Company's determined that its Services operating segment no longer meets the quantitative thresholds of a reportable segment and did not meet the aggregation criteria set forth in Accounting Standards Codification 280, Segment Reporting, and as such is categorized within "All other revenues" along with "Contracts and Grants". The Company evaluates the performance of these reportable segments based on revenues and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but does not include inter-segment services. The Company does not allocate contracts and grants revenue, R D, SG A, amortization of intangible assets, interest and other income (expense) or taxes to its evaluation of the performance of these segments.

THIRD QUARTER 2025 REPORTABLE SEGMENT RESULTS

Cost of Commercial Product sales decreased $4.6 million, or 10%, to $42.6 million for the quarter ended September 30, 2025. The decrease was primarily due to lower sales of OTC NARCAN and lower Canadian sales of branded NARCAN , partially offset by an increase in KLOXXADO sales

Commercial Products gross margin decreased $15.8 million, or 41%, to $22.9 million for the quarter ended September 30, 2025. Commercial Products gross margin percentage decreased 10 percentage points to 31% for the quarter ended September 30, 2025. The decrease was largely due to lower sales of OTC NARCAN and lower branded NARCAN sales, as well as an unfavorable price and volume mix, partially offset by an increase in KLOXXADO sales. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $9.4 million.

Cost of MCM product sales decreased $15.9 million, or 29%, to $38.1 million for the quarter ended September 30, 2025. The decrease was primarily due to lower production costs of ACAM2000 , BioThrax , and CNJ-016 (VIGIV), reflecting reduced volumes, combined with favorable manufacturing variances due to lower shut-down and severance costs, partially offset by an increase in costs related to higher BAT sales volume.

MCM Product gross margin decreased $15.8 million, or 14%, to $97.5 million for the quarter ended September 30, 2025. MCM Product gross margin percentage increased 3 percentage points to 68% for the quarter ended September 30, 2025. The increase in gross margin percentage was primarily due to a favorable sales mix which was weighted more heavily towards higher margin products and a decrease in shutdown and severance related costs compared with the third quarter of 2024. MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $6.9 million and restructuring costs of $0.2 million.

YTD 2025 REPORTABLE SEGMENT RESULTS

Cost of Commercial Product sales decreased $49.2 million, or 32%, to $103.5 million for the nine months ended September 30, 2025. The decrease was primarily due to lower sales of OTC NARCAN and lower Canadian sales of branded NARCAN , partially offset by an increase in KLOXXADO sales.

Commercial Products gross margin decreased $96.9 million, or 63%, to $55.9 million for the nine months ended September 30, 2025. Commercial Products gross margin percentage decreased 16 percentage points to 30% for the nine months ended September 30, 2025. The decrease was largely due to lower sales of OTC NARCAN and lower branded NARCAN sales, as well as an unfavorable price, volume and product mix, partially offset by an increase in KLOXXADO sales. Commercial Products segment adjusted gross margin in the current year period excludes the impact of intangible asset amortization of $28.3 million and restructuring costs of $0.2 million.

Cost of MCM product sales decreased $33.2 million, or 23%, to $114.1 million for the nine months ended September 30, 2025. The decrease was primarily due to lower productions costs of CYFENDUS , BioThrax , and ACAM2000 reflecting reduced volumes, no RSDL related costs in 2025 due to the sale of RSDL to SERB in the third quarter of 2024, combined with favorable manufacturing variances mostly due to lower shut-down and severance costs and lower Raxibacumab inventory reserves. These decreases were partially offset by higher costs for Anthrasil , TEMBEXA , CNJ-016 (VIGIV) sales due to higher unit volume.

MCM Product gross margin decreased $2.3 million, or 1%, to $222.9 million for the nine months ended September 30, 2025. MCM Product gross margin percentage increased 5 percentage points to 62% for the nine months ended September 30, 2025. The increase in gross margin percentage was primarily due to a favorable sales mix which was weighted more heavily towards higher margin products and a decrease in shutdown and severance costs compared with the prior year period. MCM Product segment adjusted gross margin in the current year period excludes the impacts of intangible asset amortization of $20.5 million, inventory step-up provision of $1.8 million and restructuring costs of $(1.0) million.

2025 FINANCIAL FORECAST

The Company provides the following updated financial forecast for full year 2025, reflecting management's expectations based on the most current information available.

(1) All financial information included in this release is unaudited.

(2) See "Non-GAAP Financial Measures" and the "Reconciliation of Non-GAAP Financial Measures" tables for the definitions and reconciliations of these non-GAAP financial measures to the most closely related GAAP financial measures.

(3) Our MCM Products revenue in 2025 and forecasted revenue excludes revenues related to RSDL , which was sold during the third quarter of 2024.

(4) Product sales, net are reported net of variable consideration including returns, rebates, wholesaler fees and prompt pay discounts in accordance with GAAP.

(5) Our Commercial Products forecast consists of revenues for NARCAN Nasal Spray and revenues from distribution of KLOXXADO naloxone HCl nasal spray 8 mg pursuant to an agreement with Hikma Pharmaceuticals PLC in January 2025.

CONFERENCE CALL, PRESENTATION SUPPLEMENT AND WEBCAST INFORMATION

Company management will host a conference call at 5 00 pm eastern time today, October 29, 2025, to discuss these financial results. The conference call and presentation supplement can be accessed from the Company's website or through the following

Advanced registration is required.

Visit https register-conf.media-server.com register BI87c9854c104a472e92d2ff019fcc47cf to register and receive an email with the dial-in number, passcode and registrant ID.

Visit https edge.media-server.com mmc p azeu358t

A replay of the call can be accessed from the Emergent website.

ABOUT EMERGENT BIOSOLUTIONS INC.

NON-GAAP FINANCIAL MEASURES

In the accompanying analysis of financial information, we sometimes use information derived from consolidated and segment financial information that may not be presented in our financial statements or prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Certain of these financial measures are considered not in conformity with GAAP ("non-GAAP financial measures") under the United States Securities and Exchange Commission ("SEC") rules. Specifically, we have referred to the following non-GAAP financial measures

Adjusted Net Income (Loss)

Adjusted Net Income (Loss) per Diluted Share

Adjusted EBITDA Margin

Adjusted Gross Margin

Adjusted Gross Margin %

Segment Adjusted Gross Margin

Segment Adjusted Gross Margin %

We define Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share, which are non-GAAP financial measures, as net income (loss) and net income (loss) per diluted share, respectively, excluding the impact of non-cash amortization charges, impairments, severance and restructuring costs, inventory step-up provision, acquisition and divestiture costs, exit and disposal costs, loss (gain) on sale of business and assets held for sale, settlement charges, net, contingent consideration milestones, changes in fair value of financial instruments, other expense (income) items and tax effects. We use Adjusted Net Income (Loss) for the purpose of calculating Adjusted Net Income (Loss) per Diluted Share. Management uses Adjusted Net Income (Loss) per Diluted Share to assess total Company operating performance on a consistent basis. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with an additional understanding of our business operating results, including underlying trends.

We define Adjusted EBITDA, which is a non-GAAP financial measure, as net income (loss) before depreciation and amortization, income tax provision, interest expense, net, excluding the impact of changes in fair value of financial instruments, acquisition and divestiture costs, severance and restructuring costs, loss (gain) on sale of business and assets held for sale, inventory step-up provision, contingent consideration milestones, impairments, settlement charges, net, exit and disposal costs and other expense (income) items. We define Adjusted EBITDA Margin, which is a non-GAAP financial measure, as Adjusted EBITDA divided by Total Revenues. We believe that these non-GAAP financial measures, when considered together with our GAAP financial results and GAAP financial measures, provide management and investors with a more complete understanding of our operating results, including underlying trends. In addition, EBITDA is a common alternative measure of operating performance used by many of our competitors. It is used by investors, financial analysts, rating agencies and others to value and compare the financial performance of companies in our industry, although it may be defined differently by different companies. Therefore, we also believe that this non-GAAP financial measure, considered along with corresponding GAAP financial

measures, provides management and investors with additional information for comparison of our operating results with the operating results of other companies.

We define Adjusted Gross Margin, which is a non-GAAP financial measure, as Gross Margin, excluding the impact of intangible asset amortization, restructuring costs, changes in the fair value of financial instruments, settlement charges, net and inventory step-up provision. We define Adjusted Gross Margin %, which is a non-GAAP financial measure, as Adjusted Gross Margin as a percentage of Products and services sales, net.

We define Segment Adjusted Gross Margin, which is a non-GAAP financial measure, as a segment's Gross Margin excluding the respective impact of intangible asset amortization, restructuring costs, changes in the fair value of financial instruments and inventory step-up provision. We define Segment Adjusted Gross Margin %, which is a non-GAAP financial measure, as Segment Adjusted Gross Margin as a percentage of a segment's revenues.

Non-GAAP financial measures are not defined in the same manner by all companies and may not be comparable with other similarly titled measures of other companies. The determination of the amounts that are excluded from these non-GAAP financial measures are a matter of management judgment and depend upon, among other factors, the nature of the underlying expense or income amounts. Non-GAAP financial measures should be considered in addition to, but not as a substitute for or superior to, the information contained in our Consolidated Statements of Operations and Consolidated Statements of Cash Flows. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this press release.

SAFE HARBOR STATEMENT

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the objectives of our restructuring initiatives and divestitures, including our future results, projected costs, prospects, plans and objectives of management, are forward-looking statements. We generally identify forward-looking statements by using words like "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "confident," "commit," "forecast," "future," "outlook," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. These forward-looking statements are based on our current intentions, beliefs, assumptions and expectations regarding future events based on information that is currently available. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement contained herein. Any such forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others, the availability of USG funding for contracts related to procurement of our medical countermeasure ("MCM") products, including CYFENDUS (Anthrax Vaccine Adsorbed (AVA) Adjuvanted), previously known as AV7909, ACAM2000 (Smallpox (Vaccinia) Vaccine, Live), CNJ-016 (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), BioThrax (Anthrax Vaccine Adsorbed) EbangaTM (ansuvimab-zykl) and or TEMBEXA (brincidofovir) among others, as well as contracts related to development of medical countermeasures our ability to meet our commitments to quality and compliance in all of our manufacturing operations our ability to negotiate additional USG procurement or follow-on contracts for our MCM products that have expired or will be expiring the commercial availability and impact of a generic and competitive marketplace on future sales of NARCAN (naloxone HCL) Nasal Spray and over-the-counter NARCAN Nasal Spray our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations our ability to negotiate new or further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing related to our bioservices and under existing Bioservices contracts our ability to collect reimbursement for raw materials and payment of service fees from our Bioservices customers the results of pending government investigations and their potential impact on our business our ability to satisfy the conditions of our litigation settlement agreements, and the potential impact of such agreements, including the funds to resolve related litigation, on our business our ability to comply with the operating and financial covenants required by (i) our term loan facility under a credit agreement, dated August 30, 2024, among the Company, the lenders from time to time party thereto and OHA Agency LLC, as administrative agent, (ii) our revolving credit facility under a credit agreement, dated September 30, 2024, among the Company, certain subsidiary borrowers, the lenders from